stockportfolio.pro
Stocks / BIO vs HALO
BIO vs HALO
Bio-Rad Laboratories, Inc. and Halozyme Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bio-Rad Laboratories, Inc. (BIO) | Halozyme Therapeutics, Inc. (HALO) | |
|---|---|---|
| Market cap | $7.8B | $8.4B |
| Revenue (latest FY) | $2.58B | $1.40B |
| Net income (latest FY) | $759.90M | $316.89M |
| Revenue growth (5y CAGR) | 0.3% | 39.2% |
| Net margin | 29.4% | 22.7% |
| Return on equity | 10.2% | 649.2% |
| P/E ratio | 48.8 | 24.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BIO — free Open HALO — freeFrequently asked questions
Which is bigger, BIO or HALO?
Halozyme Therapeutics, Inc. is larger by market capitalization — $8.4B versus $7.8B.
Which grows faster, BIO or HALO?
Over the last five fiscal years, Halozyme Therapeutics, Inc. grew revenue faster — 39.2%/yr versus 0.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.